Male sex is associated with unfavourable pharmacokinetics and prognosis in elderly patients with diffuse large B-cell lymphoma (DLBCL). We investigated higher rituximab doses for elderly male DLBCL patients. Elderly patients (61-80 years) received 6 cycles CHOP-14 (cyclophosphamide, doxorubicin, vincristine and prednisone at 14-day intervals) and were randomized to 8 cycles rituximab (males 500 mg/m 2 , females 375 mg/m 2 ) every 2 weeks or according to an upfront dose-dense schedule. In 268 (120 females, 148 males) no difference between the standard and the upfront dose-dense rituximab schedule was found (3-year PFS 72% vs. 74%; OS 74% vs. 77%; P = 0.651). The 500 mg/m 2 dose of rituximab for male patients was associated with serum levels and exposure times slightly better than in females and a male/female hazard ratio of 0.9 for progression-free survival (PFS) and 0.8 for overall survival. For elderly males, 500 mg/m 2 was not more toxic than 375 mg/m 2 rituximab, but improved PFS by 32.5% (P = 0.039), with a trend for a (30%) better overall survival (P = 0.076) in a planned subgroup analysis adjusting for International Prognostic Index risk factors. We conclude that the higher rituximab dose for elderly male patients abrogated the adverse prognosis of male sex without increasing toxicity. In the era of personalized medicine, sex-specific pharmacokinetics and toxicities should be investigated for all drugs where these parameters impact on outcome.
The combination of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) and rituximab is considered standard for the treatment of diffuse large B-cell lymphoma (DLBCL) (Coiffier et al, 2002; Habermann et al, 2006; Pfreundschuh et al, 2006 Pfreundschuh et al, , 2008 . We have shown that male sex becomes a significant risk factor in elderly patients with DLBCL when rituximab is added to CHOP, but is not significant when patients are treated with CHOP alone (Muller et al, 2012; Pfreundschuh et al, 2014a) . Indeed, in all three German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) trials of elderly DLBCL patients where rituximab was given with CHOP at a dose of 375 mg/m 2 , males fared significantly worse than females, while this was not the case in three trials without rituximab (Muller et al, 2012; Pfreundschuh et al, 2014a) . Pharmacokinetic studies revealed that elderly male patients have a significantly faster rituximab clearance than elderly females, resulting in a shorter rituximab serum elimination half-life, lower peak and trough serum levels and shorter rituximab exposure times (Muller et al, 2012; Pfreundschuh et al, 2014a) . To address the question of whether increasing the rituximab dose in elderly males would result in more favourable rituximab pharmacokinetics and a better outcome we designed the SEXIE-R-CHOP-14 study, where elderly males received a one-third higher rituximab dose than females. Moreover, given that rituximab trough serum levels increase slowly and do not achieve a maximum until the last application of rituximab when given at 2-week or 3-week intervals, we hypothesized that an upfront dose-dense application of rituximab could improve its efficacy and therefore randomized all patients to receive rituximab every 2 weeks or according to an upfront dose-dense schedule.
Methods

Patients
The study was conducted in accordance with the Helsinki declaration. The protocol was approved by the ethical review committee of each participating centre and all patients gave written informed consent. Eligibility criteria were identical with those in the RICOVER-60 (Rituximab with CHOP over age 60 years) trial : previously untreated, biopsy-confirmed aggressive non-Hodgkin lymphoma of the B-cell type and age between 61 and 80 years. Diagnostic samples were reviewed by a panel of 5 expert haematopathologists according to the 2008 World Health Organization (WHO) classification (Swerdlow et al, 2008) . Patients with human immunodeficiency virus-associated lymphoma, a history of indolent lymphoma or other neoplasms, marked impairment of cardiac, pulmonary, hepatic or renal function, WHO performance status >3 after pre-phase treatment (see below), initial white blood cell count (WBC) <2Á5 9 10 9 /l, initial platelet <100 9 10 9 /l, or inability to comply with study requirements were excluded. The patients had mandatory baseline examinations including clinical examination, relevant laboratory tests, computed tomography (CT) of neck, chest, abdomen and pelvis, and a bone marrow biopsy. CT scans were centrally reviewed. Positron emission tomography-CTs were not performed because they are not covered by health insurances in Germany.
Treatment
A 'pre-phase' treatment [single injection of 1 mg vincristine (i.v.) and 100 mg prednisone (p.o.) for 7 days] was mandatory to improve the performance status of the patients and to ameliorate the side-effects of the first chemotherapy cycle. Levofloxacin 500 mg was recommended when the WBC dropped below 1Á0 9 10 9 /l. Cytomegalovirus (CMV) and pneumocystis jiroveci prophylaxis with aciclovir (4 9 400 mg/ day) and cotrimoxazole (2 double-strength tablets every Saturday and Sunday), respectively, was mandatory. This prophylaxis had been introduced in the previous DENSE-R-CHOP-14 trial (Murawski et al, 2014) 3, 7, 15, 29, 43, and 57 . Granulocyte colony-stimulating factor support was mandatory. The next chemotherapy cycle was scheduled for day 15, after recovery of WBC to >2Á5 9 10 9 /l and platelet count to >80 9 10 9 /l. Patients with initial bulky disease (lymphoma masses or conglomerates with a diameter ≥7Á5 cm) or extranodal involvement received radiotherapy (36 Gy) to these areas. Radiotherapy plans were devised centrally. All patients underwent restaging after 3 cycles of chemotherapy and after the end of treatment. Follow-up examinations were performed every 3 months during the first 2 years, and every 6 months during the third to fifth year by use of physical examination, relevant laboratory tests and CT of the neck, chest, abdomen and pelvis. Response was assessed by the treating physician and classified as complete response (CR), unconfirmed complete response (CRu), partial response (PR), stable disease or progressive disease according to the International Workshop criteria (Cheson et al, 1999) . Adverse events reported were coded on the casereport forms according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) v3Á0 grades (http:// ctep.cancer.gov/protocolDevelopment/electronic_appli cations/docs/ctcaev3.pdf).
Rituximab pharmacokinetics
A pharmacokinetic study was performed in 80 patients (20 male and 20 female patients each treated with the 2-week and the dense up-front rituximab schedule, respectively). As in RICOVER-60, all patients included in the pharmacokinetic study had normal kidney and liver functions. Blood sampling and rituximab enzyme-linked immunosorbent assays were performed as described previously (Muller et al, 2012) . Pharmacokinetic properties (population model building, pharmacokinetic analysis and model validation) of rituximab were processed and analysed using the nonlinear mixed effect approach (NONMEM) as described (Muller et al, 2012) . The statistical analysis of the demographic data of the pharmacokinetic study was done using IBM SPSS version 19.0.0 (SPSS Inc., Ehningen, Germany).
Study design and statistical analysis
The primary objective of the SEXIE-R trial was the evaluation of the pharmacokinetics, safety and toxicity of the SEXIE-R-CHOP-14 ª 2017 John Wiley & Sons Ltd upfront dose-dense rituximab schedule and the increased dose of 500 mg/m 2 for elderly males. Treatment-related death rate was used as one of the important toxicity criteria of plan the sample size. The accuracy should be demonstrated by means of the rate of treatment-related deaths with 95% confidence interval (CI). With a planned sample size of 332 patients it would be possible to estimate the 95% CI with a precision of about 6% assuming a treatment-related death rate of 6%. To answer the pharmacokinetic questions 20 patients each (male/female) from the 2-week and denseupfront arm were planned. The secondary endpoints of the study were the progression-free (PFS) and overall survival (OS), the definitions of which were identical to those used in the RICOVER-60 trial .
In the SEXIE-R-CHOP-14 trial patients were randomized to two treatment arms (2-week rituximab or upfront dosedense rituximab; Fig 1) using the database and were stratified according to centre, International Prognostic Index (IPI) (1-2 vs. 3-5), >1 extranodal involvement or bulky disease (no vs. yes), age (≤70 years vs. >70 years) and sex. To gain rapid information on the feasibility and toxicity of the upfront dose-dense rituximab schedule, the first 200 patients were randomized 2:1. In an interim analysis, the upfront dosedense dosing was found to be feasible. Subsequently, the trial sample size was upgraded in a formal amendment to 300 patients to enable reliable estimation of PFS and OS and the randomization ratio was adjusted to approximate equal arm contributions. This was not fully achieved, as the trial recruitment had to be terminated after inclusion of 271 patients due to termination of insurance policies. Despite the somewhat lower number of patients, the estimation of the primary endpoint was possible with nearly the same precision of estimations (e.g. for the estimated treatment-related death rate of 6% the precision of the 95% CI remained 6% with 268 evaluable instead of the 332 planned patients).
The treatment results of this trial were then compared in a planned additional analysis with the 610 patients treated within the RICOVER-60 trial with the same immunochemotherapy in combination with the standard dose and schedule of rituximab (8 applications of 375 mg/ m 2 every 2 weeks for both male and female patients).
Patient characteristics and NCI-CTC toxicities between treatment arms were compared by using chi-square tests and, if required, by Fisher's exact tests. For estimating the treatment duration and dose erosion the technique of KaplanMeier estimators were used as described before (Wunderlich et al, 2003) . PFS and OS were estimated according to the method of Kaplan and Meier and for comparisons log rank tests were used. The estimators at 2 and 3 years are given with the 95% CI. Multivariate analyses were performed using a Cox proportional regression model adjusting for IPI factors and gender. The significance level was 5% (two-sided). Statistical software SPSS (version 19Á0) was used for analyses. The SEXIE-R-CHOP-14 study was performed as an amendment to the CHOP-R-escalted protocol and was registered under NCT00290667 with the last update as of 11 September 2011.
Results
Between September 2009 and September 2012, 42 centres recruited 271 consecutive DLBCL patients aged 61-80 years. Informed consent was withdrawn by three patients after randomization, leaving 268 evaluable patients. Pathology review was performed in 98Á5% of these patients. A CONSORT diagram of the study is shown in Fig 1. The characteristics of the patients in this trial are shown in Table I . There were no significant differences between the two treatment arms (Table I) .
Rituximab pharmacokinetics
The trough serum levels of rituximab are shown in Fig 2. The serum levels were higher with the upfront dose-dense schedule, but relevant rituximab exposure times above the putative threshold of 25 lg/ml (Vidal et al, 2009) were shorter. While the rituximab exposure time was 184 days for both female and male patients with the upfront dose-dense schedule, the exposure time was longer in males (264 days) compared to females (238 days) with the 2-week application of rituximab (Fig 2A) .
Protocol adherence
Protocol adherence was excellent, with median relative doses of 99% for doxorubicin and cyclophosphamide, 100% for prednisone, but only 88% for vincristine due to polyneuropathy, with no differences between treatment arms. The median relative doses for rituximab were 100% both in females and males and the median absolute dose was as planed 3000 mg/m 2 in female and 4000 mg/m 2 in male patients, who received single doses of 375 mg/m 2 and 500 mg/m 2 , respectively. There were no differences in the rituximab doses received in females nor males, proving that 34 (60%) 41 (50%) 41 (65%) 76 (62%) 82 (57%)
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11 ( 19%) 21 (26%) 23 (37%) 32 (26%) 44 ( 18 (32%) 19 (23%) 14 (22%) 35 (29%) 33 ( there was no interaction between the treatment arms and the planned rituximab doses. The cumulative dose plots for rituximab are shown in Figures S1 and S2. The planned duration for 6 courses R-CHOP was 71 days and the median treatment duration achieved was comparable between male and female patients ( Figure S3 ). It was the same in both treatment arms: 2-week rituximab: males 71, females 75 days; upfront dose-dense rituximab: males 72, females 73 days). All patients with bulky disease and/or extralymphatic involvement were planned to receive radiotherapy (36 Gy), and there were no differences between the four treatment arms with respect to the fraction of patients with bulky disease and/or extralymphatic involvement who received the planned radiotherapy (2-week rituximab: males 72%, females 71%; upfront dose-dense rituximab: males 60%, females 66%).
Toxicity
There was a tendency that the upfront dose-dense schedule of rituximab was associated with more myelosuppression compared to the standard schedule, but the differences between the treatment arms were not significant (Table II) . Treatment-related death rates, rates of CTC grades 3 and 4 leucocytopenia, thrombocytopenia and anaemia were higher in females than males in both treatment arms (Table II) .
Treatment outcome
There were no differences between the 2-week vs. the upfront dose-dense rituximab schedule with respect to PFS (2-year rates: 76% vs. 77%; 3-year rates 72% vs. 74%; P = 0Á998) and OS (2-year rates 81% vs. 83%; 3-year rates: 74% vs. 77%; P = 0Á651; Fig 3A) . These results were confirmed in a multivariate analysis adjusting for IPI factors and sex (Table IIIA) . There were no differences with respect to PFS and OS between the first 200 patients (randomized to the upfront dose-dense rituximab schedule at a ratio of 2:1) and the rest (randomized 1:3; data not shown).
Because there were no differences between the 2-week and the upfront dose-dense rituximab in SEXIE-R-CHOP-14 and no interactions between the treatment arms and rituximab doses ( Figures S2 and S3 ), both schedules were combined for the analysis of sex differences. Although males received higher rituximab doses, there was no difference with respect to PFS and OS compared to females (Fig 3B) . The 2-year PFS was 79% (95%-CI: 72; 86) and 74% (95%-CI: 66; 82), and OS was 86% (95%-CI: 80; 91) and 78% (95%-CI: 70; 85) for males and females, respectively. In a multivariate analysis adjusting for the IPI risk factors, the male hazard was 0Á9 (0Á6; 1Á5; P = 0Á797) for PFS and 0Á8 (0Á5; 1Á3; P = 0Á427) for OS.
Planned additional analyses
Additional analyses were performed in a planned historical comparison and subgroup analysis of the SEXIE-R-CHOP-14 study with 610 patients (325 males and 285 females) from the RICOVER-60 study who had received 6 9 CHOP-14 plus eight 2-week applications of rituximab (375 mg/m 2 for both female and male patients).
The characteristics of the patients in the SEXIE-R-CHOP-14 and the RICOVER-60 studies are compared in Table S1 . levels (P < 0Á001) and longer relevant rituximab exposure times (264 vs. 206 days; P < 0Á001; Fig 2B) . Most importantly, the increased rituximab dose for male patients in the SEXIE-R-CHOP-14 trial did not result in higher toxicity in comparison to the RICOVER-60 trial. CTC grades 3 and 4 of leucocytopenia, thrombocytopenia and anaemia in elderly males receiving the standard 2-week schedule of 500 mg/m 2 rituximab were practically identical with the myelosuppression observed in elderly male patients in the RICOVER-60 study where males had received 8 9 375 mg/m 2 at the standard 2-week schedule with 6 cycles of CHOP-14 (Table II) . CTC-grade 3 and 4 infections were even lower in SEXIE-R-CHOP-14, most likely due to the anti-infective prophylaxis with cotrimoxazole and acyclovir, which was mandatory in the SEXIE-R-CHOP14 trial. The treatment-related death rate was 6% with 95% CI (3%; 9%) in the total SEXIE-R-CHOP-14 study, which was nearly identical to that of 610 patients in the RICOVER-60 trial [7% with 95% CI (5%; 9%)] with 6 cycles of chemotherapy and the standard rituximab schedule. While PFS and OS were slightly better for males compared to females in the SEXIE-R-CHOP-14 trial (see above), the reverse had been observed in the RICOVER-60 study . After a median time of observation of 34 months, 2-year PFS in RICOVER-60 had been 71% (95%-CI: 66; 76) vs. 77% (95%-CI: 72; 82) and 2-year OS 76% (95%-CI: 71; 81) vs. 80% (95%-CI: 75; 85) for males and females, respectively. The respective 3-year rates are shown in Table S2 . This became even more evident in a multivariate analysis adjusting for the IPI risk factors: as can be seen from Table IIB, the male hazard ratio (HR), which had been significant in 610 (285 female and 325 male) patients in RICOVER-60, was reversed, from 1Á6 (95%-CI: 1Á2; 2Á2; P = 0Á004) to 0Á9 (0Á6; 1Á5; P = 0Á797) for PFS and from 1Á4 (1Á0; 1Á9; P = 0Á063) to 0Á8 (0Á5; 1Á3; P = 0Á427) for OS, while there were no HR differences for females between RICOVER-60 and SEXIE-R-CHOP-14. The male hazard ratios for PFS (0Á9; P = 0Á797) and OS (0Á8; P = 0Á427) in the SEXIE-R-CHOP-14 study were outside the 95% CIs (PFS: 1Á2; 2Á2; OS: 1Á0; 1Á9) of the respective HRs in RICOVER-60 . Moreover, when the outcome of male patients in the SEXIE-R-CHOP-14 and RICOVER-60 trial were compared in a multivariate analysis adjusting for the IPI risk factors, the increased dose in the SEXIE-R-CHOP-14 trial was associated with a significantly (32Á5%) better PFS (HR 0Á675; 95%-CI 0Á5; 1Á0; P = 0Á039) and a trend for a (30Á2%) better OS (HR 0Á698; 95%-CI 0Á5; 1Á0; P = 0Á076; Table IIIC ).
Discussion
The schedule and dosing of rituximab in combination with CHOP chemotherapy for DLBCL (Coiffier et al, 2002 ) is based on practical and/or historical reasons and not on scientific data, carrying the risk of suboptimal dosing, and NCI-CTC, National Cancer Institute common Toxicity Criteria; R, rituximab. *Blood counts were checked twice weekly and at least once between days 8 and 11 (during the expected nadir) of each cycle. †In the RICOVER-60 trial only patients who received 6 cycles of R-CHOP-14 + 2R are shown (for better comparability, patients who received 8 cycles R-CHOP-14 are excluded). ‡Denser-up: rituximab was given with an upfront dose-dense schedule on days -1, 0, 3, 7, 15, 29, 43, and 57.
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ª 2017 John Wiley & Sons Ltd Tables IIIA and B. therefore may not exploit the whole therapeutic potential of rituximab. All studies of combined chemoimmunotherapy in DLBCL used the standard dose (375 mg/m 2 ) and the pharmacokinetic impact of modifying doses and intervals was not analysed until recently (Muller et al, 2012; Pfreundschuh et al, 2014a) , when we showed that elderly males had unfavourable pharmacokinetics and worse outcome than elderly female patients with DLBCL. Therefore, we addressed two questions in the SEXIE-R-CHOP-14 study: firstly, can results obtained with eight 2-week applications of rituximab be improved by an upfront dose-dense schedule with the last administration given on day 57? and secondly, can the adverse prognostic impact of male sex in elderly DLBCL patients be abrogated by increasing the rituximab dose in elderly males by one-third? The randomized comparison of the upfront dose-dense with the 2-week rituximab schedule showed equal efficacy of the dose-dense schedule with a slightly increased myelotoxicity. With respect to the second question, the prognostic impact of male sex, this study showed that increasing the rituximab dose in elderly males by one-third (500 mg/m 2 instead of 375 mg/m 2 ) did indeed abrogate the adverse prognosis of elderly male patients.
Additional planned analyses addressed differences in the outcome of elderly patients with DLBCL between the SEXIE-R-CHOP-14 and the RICOVER-60 studies. With all the caveats of such a historical comparison, this analysis should lend further support that increasing the rituximab dose would improve the outcome of elderly male patients, particularly in light of the fact that protocol adherence was excellent (actually identical) in both trials. While the less favourable rituximab pharmacokinetics, i.e. lower serum levels and shorter exposure times, in male patients had been associated with a significantly worse outcome in RICOVER-60, it remained to be shown that higher rituximab serum levels and/or exposure times in elderly male patients would improve their outcome. The increase by one-third had been chosen based on calculations derived from the serum levels of male and female patients in the RICOVER-60 study with the aim to achieve similar rituximab serum levels in both sexes (Muller et al, 2012; Pfreundschuh et al, 2014a) . As shown in Fig 2, this target was quite well met. The increase of the rituximab dose by one-third resulted in slightly higher serum levels in male compared to female patients, and, of note, the higher rituximab doses of male patients were not (Table II) . After elderly males had fared significantly worse than females in all three prospective DSHNHL trials where rituximab had been given at a dose of 375 mg/m 2 together with CHOP chemotherapy, but not in three trials where CHOP was given without rituximab (Pfreundschuh et al, 2014a) , the aim of this study was to demonstrate that the worse prognosis of elderly male patients compared to females can be abrogated by an increased rituximab dose in a prospective study. This goal was met in the SEXIE-R-CHOP-14 trial: a multivariate analysis adjusting for IPI risk factors (Table IIIA) showed that the higher rituximab dose resulted in a better outcome of elderly male patients compared to female patients with DLBCL to such an extent that the male HR for PFS (0Á9) and OS (0Á8) in the SEXIE-R-CHOP-14 trial was outside the 95% CIs of the male HR observed in the RICOVER-60 study (95%-CI PFS = 1Á2-2Á2; 95%-CI OS = 1Á0-1Á9). Moreover, a second multivariate analysis adjusting for IPI risk factors (Table IIIB) demonstrated that the higher rituximab dose for elderly male patients resulted in a 32Á5% better PFS, which was significant (P = 0Á039) and a trend for a better OS (30%; P = 0Á076). However, while prospectively addressed and supported by the pharmacokinetic data in the SEXIE-R-CHOP-14 trial, the latter (planned) comparison (375 mg/m 2 for elderly males in RICOVER-60; 500 mg/m 2 in SEXIE-R-CHOP-14) is a historical (yet planned) one with all its caveats. In addition, the fact that there were no differences between RICOVER-60 and SEXIE-R-CHOP-14 for females in the multivariate analysis, further supports the validity of this historical comparison, and the results of the multivariate analyses that adjust for variations in the respective study population serve as a solid basis for the ongoing OPTIMAL>60 study of the DSHNHL (NCT01478542), where higher rituximab serum levels and exposure times for males and females are being investigated in a randomized fashion in elderly DLBCL patients. While the SEXIE-R-CHOP-14 trial demonstrates that 375 mg/m 2 rituximab is suboptimal for elderly male patients, it is unclear whether this dose is optimal for elderly females; that there was a tendency that the higher dosed males did better than the females in SEXIE-R-CHOP14 suggests that further improvement might also be possible for elderly females by increasing rituximab doses and/or exposure times. Similarly, we would expect a better outcome with increased rituximab doses also for young female and young male patients with DLBCL, both of whom also have a significantly faster clearance than elderly females (Pfreundschuh et al, 2014a) . Our results shed also light on the claimed superiority of new CD20 antibodies, which are given at higher doses and/or more often than rituximab (Goede et al, 2014) : given that rituximab 375 mg/m 2 is a suboptimal dose and that this drugs efficacy can be improved with higher doses, the relative efficacy of new CD20 antibodies compared to rituximab can only be determined if these antibodies are studied at the same dose and schedule as rituximab. Increasing the rituximab dose by one-third resulted both in significantly higher (P < 0Á001) serum levels and longer (P < 0Á001) exposure times above the putative threshold of 25 lg/ml (Vidal et al, 2009) . Given that the higher rituximab serum levels achieved by four additional rituximab applications during the first 3 weeks of treatment in the DENSE-R-CHOP-14 trial (Murawski et al, 2014) did not result in a better outcome, while 8 applications given over an extended period trial resulted in lower trough serum levels, but significantly longer relevant rituximab exposure times (i. e. levels above the putative efficacy threshold of 25 lg/ml (Vidal et al, 2009 ) and were associated with a better outcome, particularly for elderly males in the SMARTE-R-CHOP-14 study (Pfreundschuh et al, 2014b) , we believe that the improved outcome observed in elderly males receiving 500 mg/m 2 in SEXIE-R-CHOP-14 is due to the longer exposure times rather than the increased serum levels of rituximab. This is also supported by the recent observation in the GOYA trial where the novel CD20 antibody obinutuzumab, which was given at a considerably higher dose than rituximab (1000 mg vs. 375 mg/m 2 , respectively) failed to improve the outcome of patients with DLBCL (Chiappella et al, 2017) . Finally, the observation in the NHL13 trial (Jaeger et al, 2015) , where male patients in contrast to female patients benefitted from rituximab maintenance treatment, also favours the hypothesis that extending relevant exposure times of rituximab is a more promising strategy than increasing its dose. Our results in elderly DLBCL patients are not in conflict with the results of rituximab maintenance after high-dose chemotherapy and autologous stem cell transplantation in young patients with DLBCL in the CORAL study (Gisselbrecht et al, 2012) , in which young females, but not young males benefitted from more (i.e. maintenance) rituximab. Due to the steep decrease of rituximab clearance in females with age, young females have a faster rituximab clearance than young males with DLBCL (Pfreundschuh et al, 2014a) and hence shorter exposure times; the latter can explain the better effect of maintenance rituximab in the (young) female CORAL population. Similarly, the efficacy of the i.v. and s.c. routes of administration in the MABEASE trial (Lugtenburg et al, 2017) are in line with this interpretation because the pharmacokinetics of 1400 mg rituximab sc do not provide longer exposure times (Davies et al, 2014) compared to 375 m/m 2 iv. Although higher (i.v.) rituximab doses would be associated with higher costs the availability of rituximab biosimilars should mitigate this effect. Interestingly, we confirmed previous observations made by us and others that elderly female patients experience more toxicities caused by the CHOP chemotherapy than males, and it may well be that the (non-significantly) worse outcome of elderly male compared to female patients after CHOP without rituximab might be improved, if the dose of the CHOP chemotherapy were increased to equitoxicity in male patients . Similar observations have also been made in Hodgkin lymphoma, where it was shown that low haematological toxicity was an independent prognostic factor associated with a worse outcome (Brosteanu et al, 2004) . These observations suggest that increasing doses of cytotoxic agents to a degree of acceptable toxicity could be a rewarding goal in the treatment of malignant diseases with a (steep) dose-efficacy curve, a strategy pursued with the dose-adjusted EPOCH-R (rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin) protocol in aggressive lymphomas (Wilson et al, 2002) . While adjusting the rituximab dosing to an individual patient's pharmacokinetics would be a desirable consequence, this is hardly practical in daily routine. In contrast to chemotherapy doses that can be adjusted according to their myelotoxicity, this is not possible in the case of rituximab due to its low rate and grade of side effects, making pharmacokinetic measurements (which are not widely available) mandatory. However, dosing adjusted to very obvious parameters, such as sex, should be feasible, if the sex effects on toxicity and efficacy of a regimen were known. The latter, however, is rarely the case, because there are only few phase-I (dose escalation) studies that have addressed sex-specific pharmacokinetics and toxicities. In the era of personalized medicine, the experience with rituximab dosing in elderly DLBCL patients calls for such sex-specific investigations not only in clinical oncology, but also in all other fields of medicine where efficacy and toxicity of a given drug is an issue.
Authorship
MP, NM, and CZ designed and coordinated the study, participated in data analysis and wrote the manuscript. LT and NS designed the study and wrote the manuscript. SZ, MZ and ML performed the statistical analysis. MH, JD, UK, MD, LT, NF, A-NH, VP and GH coordinated the study. TR coordinated the pharmacokinetic analysis. All authors participated in writing the manuscript.
Funding
This work was supported by Deutsche Krebshilfe (a charity organization). The cost for the pharmacokinetic studies was covered by Roche.
Disclosure
Michael Pfreundschuh is on advisory boards of Amgen, Boehringer Ingelheim, Celgene, Gilead, Novartis, Pfizer, Onyx, Roche, Sandoz and Spectrum and has received research support from Amgen, Roche and Spectrum.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Fig S1 . Cumulative dose plots of absolute and relative rituximab doses in the SEXIER-CHOP-14 trial. Fig S2. Cumulative dose plots of absolute rituximab doses in the SEXIER-CHOP-14 trial according to sex and treatment arms. Fig S3. Duration of chemotherapy in the SEXIE-R-CHOP-14 trial. Table S1 . Characteristics of patients in the SEXIE-R-CHOP-14 and RICOVER-60 trials. Table S2 . 3-year survival rates in the RICOVER-60 and SEXIE-R-CHOP-14 trials.
